• Skip to main content
  • Skip to primary sidebar

Tracking Health and Wellness Applications of Brain Science

Spanish
sb-logo-with-brain
  • Resources
    • Monthly eNewsletter
    • Solving the Brain Fitness Puzzle
    • The SharpBrains Guide to Brain Fitness
    • How to evaluate brain training claims
    • Resources at a Glance
  • Brain Teasers
    • Top 25 Brain Teasers & Games for Teens and Adults
    • Brain Teasers for each Cognitive Ability
    • More Mind Teasers & Games for Adults of any Age
  • Virtual Summits
    • 2019 SharpBrains Virtual Summit
    • Speaker Roster
    • Brainnovations Pitch Contest
    • 2017 SharpBrains Virtual Summit
    • 2016 SharpBrains Virtual Summit
    • 2015 SharpBrains Virtual Summit
    • 2014 SharpBrains Virtual Summit
  • Report: Pervasive Neurotechnology
  • Report: Digital Brain Health
  • About
    • Mission & Team
    • Endorsements
    • Public Speaking
    • In the News
    • Contact Us

smoking cessation

Could I be wrong? Exploring cognitive bias, curiosity, intellectual humility, and lifelong learning

November 30, 2021 by SharpBrains

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing eight time­ly sci­en­tif­ic and indus­try news plus a few fun teasers to appre­ci­ate our unique human brains.

#1. Could I be wrong? Explor­ing research on cog­ni­tive bias, curios­i­ty, intel­lec­tu­al humil­i­ty, and life­long learning

“None of us thinks that our beliefs and atti­tudes are incor­rect; if we did, we obvi­ous­ly wouldn’t hold those beliefs and atti­tudes. Yet, despite our sense that we are usu­al­ly cor­rect, we must accept that our views may some­times turn out to be wrong. This kind of humil­i­ty isn’t sim­ply virtuous—the research sug­gests that it results in bet­ter deci­sions, rela­tion­ships, and out­comes. So, the next time you feel cer­tain about some­thing, you might stop and ask your­self: Could I be wrong?”

#2. Great inter­view on bilin­gual­ism, sports, edu­ca­tion and neu­ro­plas­tic­i­ty — en español

#3. Should old­er politi­cians, and oth­er lead­ers, under­go cog­ni­tive test­ing? The debate con­tin­ues … here are some good com­ments from the online debate we had last summer:

  • PRO: “Def­i­nite­ly. We rou­tine­ly screen appli­cants for a wide range of jobs. Apply for the police, you will be test­ed. Join the mil­i­tary, you will be eval­u­at­ed. Should we not know if a can­di­date for the high­est posi­tion in the coun­try has a seri­ous emo­tion­al, intel­lec­tu­al or psy­cho­log­i­cal impairment?”
  • CON: “I dis­agree because these tests are very bad at pre­dict­ing how good some­one would be in lead­ing a coun­try. It doesn’t require the abil­i­ty to store a lot of infor­ma­tion in your work­ing mem­o­ry. Being a good leader requires only one essen­tial thing: hav­ing the right priorities.”
  • IT DEPENDS: “Who makes the test? What cog­ni­tive met­rics do we use? The bias­es in that design could lead to sig­nif­i­cant unex­pect­ed or even inten­tion­al­ly skewed results.”

#4. Click Ther­a­peu­tics rais­es fur­ther $52M to build up dig­i­tal ther­a­peu­tics pipeline for depres­sion, insom­nia, smok­ing ces­sa­tion and more

What a year for Click and for dig­i­tal therapeutics!

#5. The Amer­i­can Med­ical Association’s (AMA) to ease access to remote Cog­ni­tive Behav­ioral Ther­a­py Monitoring

The road to heav­en is paved with good decisions…

#6. FDA-approved, Cybin-spon­sored clin­i­cial tri­al to mea­sure ketamine’s impact on the brain via Ker­nel Flow neu­roimag­ing helmet

“The word psy­che­del­ic means ‘mind-man­i­fest­ing,’ but what has been miss­ing is use­ful ‘mind-imaging’—the abil­i­ty to dynam­i­cal­ly trace the neur­al cor­re­lates of human con­scious expe­ri­ence. Con­ven­tion­al neu­roimag­ing just isn’t dynam­ic enough to study the psy­che­del­ic expe­ri­ence in the brain as it hap­pens. This study of ketamine’s psy­che­del­ic effects while wear­ing head­gear equipped with sen­sors to record brain activ­i­ty could open up new fron­tiers of under­stand­ing” — Dr. Alex Belser, Cybin’s Chief Clin­i­cal Officer

#7. Bea­con Biosig­nals rais­es $27M to scale EEG, AI-based neu­ro­bio­mark­er dis­cov­ery platform

“ana­lyz­ing EEGs is labor inten­sive and inter­pre­ta­tion of these tests can vary from one clin­i­cian to another..…Beacon Biosig­nals has assem­bled what it claims is one of the world’s largest clin­i­cal EEG data­bas­es. By apply­ing its pro­pri­etary machine-learn­ing algo­rithms to the data­base, the com­pa­ny says it has iden­ti­fied neurobiomarkers—biological indi­ca­tors that are asso­ci­at­ed with cer­tain groups of patients, drug activ­i­ty, and ther­a­peu­tic efficacy.”

#8. Amy­loid-relat­ed imag­ing abnor­mal­i­ties (ARIA) found in approx­i­mate­ly 40% of patients tak­ing “Alzheimer’s drug” Aduhelm

Not good, yet com­plete­ly pre­dictable, and let’s remem­ber this is for a “treat­ment” cost­ing as much as $100,000/ year with exact­ly ZERO proven clin­i­cal ben­e­fit: “…The researchers found 425 cas­es in the com­bined adu­canum­ab group expe­ri­enced ARIA (41.3%), and ARIA-ede­ma was iden­ti­fied in 362 patients or 35.2%. Of them, 94 (26%) had symp­toms, such as headache, con­fu­sion, dizzi­ness and nau­sea. They found ARIA-micro­he­m­or­rhage and ARIA-super­fi­cial sidero­sis in 197 patients (19.1%) and 151 patients (14.7%), respectively.”

Final­ly, Let’s Thank our unique Human Brains and Minds with a few fam­i­ly-friend­ly riddles

Q: What does, “you must come and vis­it us some­time!” actu­al­ly mean?

 

Wish­ing you and yours a Hap­py & Healthy Hanukkah, Decem­ber and Christmas,

The Sharp­Brains Team

 

Share this:

  • Tweet
  • Email
  • Print
  • Red­dit
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Education & Lifelong Learning Tagged With: aducanumab, Aduhelm, Alzheimer's drug, Beacon Biosignals, Click Therapeutics, Cognitive Behavioral Therapy Monitoring, cognitive-bias, cognitive-testing, curiosity, Cybin, depression, digital therapeutics, FDA, insomnia, intellectual humility, Kernel Flow, machine-learning, neuroimaging, neuroplasticity, psychedelic, smoking cessation

Click Therapeutics raises further $52M to build up digital therapeutics pipeline for depression, insomnia, smoking cessation and more

November 4, 2021 by SharpBrains

Get­ty Images

With Sanofi still on board, Click Ther­a­peu­tics clos­es $52M series B for dig­i­tal ther­a­peu­tics in depres­sion, chron­ic pain and more (Fierce Biotech):

Anoth­er medtech devel­op­er’s plans to cre­ate dig­i­tal ther­a­peu­tics to treat a wide range of ill­ness­es are click­ing into place, thanks to a third mul­ti­mil­lion-dol­lar invest­ment in Click Ther­a­peu­tics in bare­ly a year. [Read more…] about Click Ther­a­peu­tics rais­es fur­ther $52M to build up dig­i­tal ther­a­peu­tics pipeline for depres­sion, insom­nia, smok­ing ces­sa­tion and more

Share this:

  • Tweet
  • Email
  • Print
  • Red­dit
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: acute coronary syndrome, app-based therapeutics, chronic pain, Click Therapeutics, Clickadian, Clickheart, Clickotine, cognitive, cognitive-exercises, depression, digital therapeutics, FDA clearance, insomnia, Otsuka, smoking cessation, treat migraine, treat schizophrenia

How to intervene early to address brain/ mental health problems: Examples in depression, epilepsy and smoking cessation

July 18, 2019 by SharpBrains

How to inter­vene ear­ly: Exam­ples in depres­sion, epilep­sy and smok­ing ces­sa­tion from Sharp­Brains

We hope you enjoy this slid­edeck sup­port­ing a fas­ci­nat­ing, for­ward-look­ing ses­sion held at the 2019 Sharp­Brains Vir­tu­al Sum­mit: The Future of Brain Health (March 7–9th).  Full record­ings are avail­able for pur­chase here.

10.45am-12.15pm. How to inter­vene ear­ly: Exam­ples in depres­sion, epilep­sy and smok­ing cessation 

  • Dr. Wal­ter Green­leaf, Research Sci­en­tist at Stan­ford University’s Vir­tu­al Human Inter­ac­tion Lab
  • David B. Klein, CEO of Click Ther­a­peu­tics
  • Ana Maiques, CEO of Neu­ro­electrics
  • Chaired by: Avery Bedows, Neu­rotech­nol­o­gy Spe­cial­ist at Loup Ven­tures

Share this:

  • Tweet
  • Email
  • Print
  • Red­dit
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: brain health, Click Therapeutics, depression, epilepsy, Loup Ventures, mental health, Neuroelectrics, problems, smoking cessation, Stanford-University

Sanofi Ventures leads $17M investment in Click Therapeutics, finalist @ 2017 Brainnovations Pitch Contest

July 25, 2018 by SharpBrains

Sanofi Backs Click Ther­a­peu­tics as Dig­i­tal Med­i­cines Gain Momen­tum (Xcon­o­my):

“Drug mak­ers are mak­ing more bets on the nascent field of dig­i­tal med­i­cine. The lat­est exam­ple: Click Ther­a­peu­tics announced Mon­day that it grabbed a $17 mil­lion invest­ment led by Sanofi Ven­tures, the Cam­bridge, MA-based ven­ture cap­i­tal arm of the French phar­ma­ceu­ti­cal giant. [Read more…] about Sanofi Ven­tures leads $17M invest­ment in Click Ther­a­peu­tics, final­ist @ 2017 Brain­no­va­tions Pitch Contest

Share this:

  • Tweet
  • Email
  • Print
  • Red­dit
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: Brainnovations, cigarette smoking, Click Therapeutics, Clickotine, digital medicine, digital therapeutics, Pear Therapeutics, Sanofi Ventures, smartphone, smoking cessation, therapeutics, tobacco

Sneak preview into the future of mental health: Fully digital clinical trials to study digital therapeutics

October 5, 2016 by SharpBrains

digitaltrial——–

Click Ther­a­peu­tics™ Reports Pre­lim­i­nary Results of a 416-Par­tic­i­pant Clin­i­cal Study Demon­strat­ing Excep­tion­al Engage­ment and Effi­ca­cy of Click­o­tine®, a Patent-Pend­ing Dig­i­tal Ther­a­peu­tics™ Pro­gram for Smok­ing Ces­sa­tion (press release):

“Click Ther­a­peu­tics, Inc. (“Click”), a com­pa­ny devel­op­ing a suite of per­son­al­ized data-dri­ven dig­i­tal ther­a­peu­tics for chron­ic health con­di­tions, announces today pre­lim­i­nary results of its ful­ly remote clin­i­cal tri­al of Click­o­tine, a dig­i­tal pro­gram designed for smok­ing ces­sa­tion. [Read more…] about Sneak pre­view into the future of men­tal health: Ful­ly dig­i­tal clin­i­cal tri­als to study dig­i­tal therapeutics

Share this:

  • Tweet
  • Email
  • Print
  • Red­dit
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: Click Therapeutics, Clinical-Trial, digital health, digital therapeutics, Mental-Health, neurobehavioral, smoking cessation

Primary Sidebar

Top Articles on Brain Health and Neuroplasticity

  1. Can you grow your hippocampus? Yes. Here’s how, and why it matters
  2. How learning changes your brain
  3. To harness neuroplasticity, start with enthusiasm
  4. Three ways to protect your mental health during –and after– COVID-19
  5. Why you turn down the radio when you're lost
  6. Solving the Brain Fitness Puzzle Is the Key to Self-Empowered Aging
  7. Ten neu­rotech­nolo­gies about to trans­form brain enhance­ment & health
  8. Five reasons the future of brain enhancement is digital, pervasive and (hopefully) bright
  9. What Educators and Parents Should Know About Neuroplasticity and Dance
  10. The Ten Habits of Highly Effective Brains
  11. Six tips to build resilience and prevent brain-damaging stress
  12. Can brain training work? Yes, if it meets these 5 conditions
  13. What are cognitive abilities and how to boost them?
  14. Eight Tips To Remember What You Read
  15. Twenty Must-Know Facts to Harness Neuroplasticity and Improve Brain Health

Top 10 Brain Teasers and Illusions

  1. You think you know the colors? Try the Stroop Test
  2. Check out this brief attention experiment
  3. Test your stress level
  4. Guess: Are there more brain connections or leaves in the Amazon?
  5. Quick brain teasers to flex two key men­tal mus­cles
  6. Count the Fs in this sentence
  7. Can you iden­tify Apple’s logo?
  8. Ten classic optical illu­sions to trick your mind
  9. What do you see?
  10. Fun Mental Rotation challenge
  • Check our Top 25 Brain Teasers, Games and Illusions

Join 12,437 readers exploring, at no cost, the latest in neuroplasticity and brain health.

By subscribing you agree to receive our free, monthly eNewsletter. We don't rent or sell emails collected, and you may unsubscribe at any time.

IMPORTANT: Please check your inbox or spam folder in a couple minutes and confirm your subscription.

Get In Touch!

Contact Us

660 4th Street, Suite 205,
San Francisco, CA 94107 USA

About Us

SharpBrains is an independent market research firm tracking health and performance applications of brain science. We prepare general and tailored market reports, publish consumer guides, produce an annual global and virtual conference, and provide strategic advisory services.

© 2023 SharpBrains. All Rights Reserved - Privacy Policy